Salud financiera de hoja de balance de Avadel Pharmaceuticals
Salud financiera controles de criterios 4/6
Avadel Pharmaceuticals tiene un patrimonio de los accionistas total de $78.4M y una deuda total de $34.3M, lo que sitúa su ratio deuda-patrimonio en 43.8%. Sus activos y pasivos totales son $167.9M y $89.5M respectivamente.
Información clave
50.5%
Ratio deuda-patrimonio
US$35.49m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$71.38m |
| Patrimonio | US$70.29m |
| Total pasivo | US$87.23m |
| Activos totales | US$157.52m |
Actualizaciones recientes sobre salud financiera
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10
Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Recent updates
Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?
Feb 05
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($136.0M) de AVDL superan a sus pasivos a corto plazo ($47.8M).
Pasivo a largo plazo: Los activos a corto plazo de AVDL ($136.0M) superan a sus pasivos a largo plazo ($41.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: AVDL tiene más efectivo que su deuda total.
Reducción de la deuda: AVDL tenía patrimonio neto negativo hace 5 años, pero ahora es positivo y, por lo tanto, ha mejorado.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: AVDL tiene menos de un año de cash runway basado en su flujo de caja libre actual.
Pronóstico de cash runway: AVDL tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 6.5% cada año